Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation

Bone Marrow Transplant. 2022 Aug;57(8):1341-1343. doi: 10.1038/s41409-022-01722-6. Epub 2022 May 25.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antigens, CD34
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Lymphoma* / therapy
  • Peripheral Blood Stem Cell Transplantation*
  • Transplantation, Autologous

Substances

  • Antigens, CD34